Press Releases

Follow our journey to bring our immune-modulation products to patients


June 11, 2018

Themis Receives EMA PRIME Designation for Chikungunya Vaccine

more
March 7, 2018

CEPI Partners with Themis Bioscience to Advance Vaccines Against Lassa Fever and MERS

more
February 26, 2018

Themis Establishes Scientific Advisory Board of Experts in Virology and Vaccine Development

more
January 4, 2018

Themis Raises EUR 10 Million in Series C Financing to Advance Clinical Pipeline

more
November 6, 2017

Themis to Present Phase 2 Interim Results for Chikungunya Vaccine Candidate at ASTMH 2017 Annual Meeting

more
September 5, 2017

Chikungunya Vaccine Development Towards Phase III Trials Boosted by Innovate UK

more
July 27, 2017

Chikungunya-Fever: Themis Bioscience Starts Phase II Clinical Study in Endemic Area

more
June 6, 2017

NIH and Themis Bioscience Announce the Initiation of a Clinical Trial of a Chikungunya Vaccine

more
April 11, 2017

Zika Virus: Themis Bioscience Initiates Worldwide First Study With Live Attenuated Recombinant Vaccine

more
December 13, 2016

Zika Virus: Top EU-Groups Join Forces in Quest for Vaccine

more
November 28, 2016

Themis Bioscience Successfully Closes 10 M EUR Financing Round

more
September 6, 2016

Themis Bioscience: Zika Vaccine Development Receives Big Boost by Innovate UK

more